RiverVest Venture Partners is a venture capital firm that focuses on building life science companies within the biopharma and medical device sectors. Their strategy involves identifying promising research and technology, then partnering with entrepreneurs to found and fund companies that develop novel therapies and medical devices to address significant unmet patient needs and deliver strong returns to investors.
Portfolio
3
Fund Size
$1.6B
Top Stage
Series B
Last 12 Mo
1
Stage Distribution
Portfolio
3 investments
| Company | Round | Amount | Date |
|---|---|---|---|
| Sparrow Pharmaceuticals | Series B | $95M | Sep 2025 |
| Bluejay Therapeutics | Series C | $182M | May 2024 |
| Standard Bariatrics | Series B | $35M | Jun 2021 |
Top Co-Investors
RA Capital Management2 shared
U.S. Venture Partners2 shared
Forbion1 shared
OrbiMed1 shared
Frazier Life Sciences1 shared
T. Rowe Price1 shared
Wellington Management1 shared
Novo Holdings1 shared
Emergent Medical Partners1 shared
Last updated: 3 March 2026